Optimalization of Nephroprotection Using N-Acetylcysteine

Exclusion Criteria

• •Nephrotic syndrome
• •Steroids or other immunosuppressive treatment minimum during six months before the study
• •Diabetes mellitus
• •Potassium serum level \> 5.1 mEq/L
• •Albumin serum level \< 2.0mg/dL
• •Creatinine serum level \>2 mg/dl
• •Current diagnosis of heart failure New York Heart Association (NYHA) Class II-IV
• •Clinically significant valvular heart disease or second or third degree heart block without a pacemaker
• •History of hypertensive encephalopathy, cerebrovascular accident or transient ischemic cerebral attack
• •History of myocardial infarction, unstable angina pectoris, coronary bypass surgery, or any percutaneous coronary intervention
• •History of malignancy including leukemia and lymphoma (but not basal cell skin carcinoma) within the past five years
• •Pregnant or nursing women
• •Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs.
• •History of alcohol abuse
• •NSAID abuse (more than 2 doses per week)
• •Known or suspected contraindications to the study medications, including history of allergy to ACE inhibitors, AT-1 receptor blockers and N-acetylcysteine